Cardiovascular-Kidney-Metabolic Health: a presidential advisory from the American Heart Association [Internet]. https://doi.org/10.1161/CIR.0000000000001184. Accessed 17 Dec 2024.

Kadowaki T, Maegawa H, Watada H, Yabe D, Node K, Murohara T, et al. Interconnection between cardiovascular, renal and metabolic disorders: a narrative review with a focus on Japan. Diabetes Obes Metab. 2022;24(12):2283–96.

Article  PubMed  PubMed Central  Google Scholar 

Usman MS, Khan MS, Butler J. The interplay between diabetes, cardiovascular disease, and kidney disease. ADA Clin Compend. 2021;2021(1):13–8.

Article  Google Scholar 

A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) syndrome: a scientific statement from the American Heart Association | Circulation [Internet]. https://doi.org/10.1161/CIR.0000000000001186?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org. Accessed 17 Dec 2024.

Norhammar A, Bodegard J, Eriksson JW, Haller H, Linssen GCM, Banerjee A, et al. Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: a multinational, observational study across 12 countries. Diabetes Obes Metab. 2022;24(7):1277–87.

Article  PubMed  PubMed Central  Google Scholar 

BHF CVD Statistics UK Factsheet January 2025 [Internet]. https://www.bhf.org.uk/-/media/files/for-professionals/research/heart-statistics/bhf-cvd-statistics-uk-factsheet.pdf?rev=81a8015761aa4ced8bc39d7045202be5&hash=9D78ACBF5EB80FA8A9BE28C90BFBE171. Accessed 31 Jan 2025.

Diabetes UK [Internet]. Diabetes diagnoses double in the last 15 years. https://www.diabetes.org.uk/about-us/news-and-views/diabetes-diagnoses-doubled-prevalence-2021. Accessed 17 Dec 2024.

Diabetes UK [Internet]. How many people in the UK have diabetes? https://www.diabetes.org.uk/about-us/about-the-charity/our-strategy/statistics. Accessed 17 Dec 2024.

Sarafidis P, Iatridi F, Ferro C, Alexandrou ME, Fernandez-Fernandez B, Kanbay M, et al. Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA). Clin Kidney J. 2023;16(11):1885–907.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burden of CVD | Background information | CVD risk assessment and management | CKS | NICE [Internet]. https://cks.nice.org.uk/topics/cvd-risk-assessment-management/background-information/burden-of-cvd/. Accessed 17 Dec 2024.

Economics-of-Kidney-Disease-full-report_accessible.pdf [Internet]. https://www.kidneyresearchuk.org/wp-content/uploads/2023/06/Economics-of-Kidney-Disease-full-report_accessible.pdf. Accessed 17 Dec 2024.

Stiebahl S. Obesity statistics. 2025. https://commonslibrary.parliament.uk/research-briefings/sn03336/. Accessed 10 Mar 2025.

Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22.

Article  Google Scholar 

Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet Lond Engl. 2018;392(10159):2052–90.

Article  Google Scholar 

Hex N, MacDonald R, Pocock J, Uzdzinska B, Taylor M, Atkin M, et al. Estimation of the direct health and indirect societal costs of diabetes in the UK using a cost of illness model. Diabet Med. 2024;41(9): e15326.

Article  PubMed  Google Scholar 

GOV.UK [Internet]. Health matters: obesity and the food environment. https://www.gov.uk/government/publications/health-matters-obesity-and-the-food-environment/health-matters-obesity-and-the-food-environment-2. Accessed 29 Jan 2025.

Brandt EJ, Tobb K, Cambron JC, Ferdinand K, Douglass P, Nguyen PK, et al. Assessing and addressing social determinants of cardiovascular health: JACC state-of-the-art review. J Am Coll Cardiol. 2023;81(14):1368–85.

Article  PubMed  PubMed Central  Google Scholar 

Painter H, Parry E, McCann L, Dehn Lunn A, Ford J. Social needs screening in primary care: a tool in the fight for health equity? Public Health Pract. 2024;1(7): 100466.

Article  Google Scholar 

A framework for NHS action on social determinants of health | The Health Foundation [Internet]. 2022. https://www.health.org.uk/reports-and-analysis/briefings/a-framework-for-nhs-action-on-social-determinants-of-health. Accessed 26 Mar 2025.

Fisher R, Gottlieb LM, Marchis ED, Alderwick H. Assessing patients’ social risks: what can England learn from emerging evidence in the US? Br J Gen Pract. 2023;73(733):370–2.

Article  PubMed  PubMed Central  Google Scholar 

Massy ZA, Drueke TB. Combination of cardiovascular, kidney, and metabolic diseases in a syndrome named cardiovascular-kidney-metabolic, with new risk prediction equations. Kidney Int Rep. 2024;9(9):2608–18.

Article  PubMed  PubMed Central  Google Scholar 

Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023;31(22):195.

Article  Google Scholar 

American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes—2024. Diabetes Care. 2023;47(Supplement_1):S179–218.

Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–140.

Article  CAS  PubMed  Google Scholar 

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Diabetes Care | American Diabetes Association [Internet]. https://diabetesjournals.org/care/article/45/11/2753/147671/Management-of-Hyperglycemia-in-Type-2-Diabetes. Accessed 17 Dec 2024.

de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in Chronic Kidney Disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care. 2022;45(12):3075–90.

Article  PubMed  PubMed Central  Google Scholar 

Zhou L, Li W. Effectiveness and safety of finerenone in Chinese CKD patients without diabetes: a retrospective, real-world study. Int Urol Nephrol. 2024;56(12):3877–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heerspink HJL, Agarwal R, Bakris GL, Cherney DZI, Lam CSP, Neuen BL, et al. Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. Nephrol Dial Transplant. 2024;gfae132.

Theodorakis N, Nikolaou M. Integrated management of cardiovascular–renal–hepatic–metabolic syndrome: expanding roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs. Biomedicines. 2025;13(1):135.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109–21.

Article  CAS  PubMed  Google Scholar 

Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32.

Article  CAS  PubMed  Google Scholar 

TCTMD.com [Internet]. 2024. SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients. https://www.tctmd.com/news/soul-oral-semaglutide-cuts-cv-events-diabetic-patients. Accessed 29 Jan 2025.

Várkonyi TT, Pósa A, Pávó N, Pavo I. Perspectives on weight control in diabetes—Tirzepatide. Diabetes Res Clin Pract. 2023;1(202): 110770.

Article  Google Scholar 

Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med [Internet]. 2025. https://doi.org/10.1056/NEJMoa2410027.

Article  PubMed  Google Scholar 

Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299–310.

Article  CAS  PubMed  Google Scholar 

U.S FDA. FDA. FDA; 2024. FDA Approves First Medication for Obstructive Sleep Apnea. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea. Accessed 21 Jan 2025.

Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193–205.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep. 2022;7(7):1463–76.

Article  PubMed  PubMed Central  Google Scholar 

Finerenone | Drugs | BNF content published by NICE [Internet]. https://bnf.nice.org.uk/drugs/finerenone/. Accessed 17 Dec 2024.

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–29.

Article  CAS  PubMed  Google Scholar 

Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–63.

Article  CAS  PubMed  Google Scholar 

Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475–85.

Article  CAS  PubMed